PATENT CLAIM ANALYSIS

Application Number: 15877436
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["424", "133100"]

Abstract:
The present invention relates to a pharmaceutical composition comprising PD-1 antagonist and an EGFR Inhibitor. The present combination can be administered independently or separately, in a quantity which is jointly therapeutically effective for the treatment of cancer. The invention also provides the use of such a combination for the manufacture of a medicament; the use of such a combination as a medicine; a kit of part comprising such a combination; and a method of treatment of such a combination.

Claim (Index 41):
A pharmaceutical combination comprising:\n i) an isolated antibody molecule capable of binding to a human Programmed Death-1 (PD-1) comprising: (a) a heavy chain variable region (VH) comprising a HCDR1 amino acid sequence of SEQ ID NO: 1, a HCDR2 amino acid sequence of SEQ ID NO: 2, and a HCDR3 amino acid sequence of SEQ ID NO: 3; and a light chain (VL) comprising a LCDR1 amino acid sequence of SEQ ID NO: 11, a LCDR2 amino acid sequence of SEQ ID NO: 12, and a LCDR3 amino acid sequence of SEQ ID NO: 13; or (b) a VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 4, a HCDR2 amino acid sequence of SEQ ID NO: 5, and a HCDR3 amino acid sequence of SEQ ID NO: 6; and a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 14, a LCDR2 amino acid sequence of SEQ ID NO: 15, and a LCDR3 amino acid sequence of SEQ ID NO: 16; or (c) a VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 21, a HCDR2 amino acid sequence of SEQ ID NO: 22, and a HCDR3 amino acid sequence of SEQ ID NO: 23; and a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 31, a LCDR2 amino acid sequence of SEQ ID NO: 32, and a LCDR3 amino acid sequence of SEQ ID NO: 33; or (d) a VH comprises a HCDR1 amino acid sequence of SEQ ID NO: 24, a HCDR2 amino acid sequence of SEQ ID NO: 25, and a HCDR3 amino acid sequence of SEQ ID NO: 26; and a VL comprising a LCDR1 amino acid sequence of SEQ ID NO: 34, a LCDR2 amino acid sequence of SEQ ID NO: 35, and a LCDR3 amino acid sequence of SEQ ID NO: 36; and ii) Compound A, which is (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1Hbenzo[d]imidazol-2-yl)-2-methylisonicotinamide, or a pharmaceutically acceptable salt thereof, preferably the mesylate salt thereof.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 86.0
- Lexical Diversity: 1.79167
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14604415', '15751140', '14881888', '15595618', '14610837']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7363704057310068
- 35 USC 102 Novelty (BERT): 0.5252866182218212
- Combined Prediction Score: 0.7152620269800882
- Mean Citation Score: 334.040494
- Max Citation Score: 353.73898
- Similarity Product: 313.9346748092556

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test